Profile data is unavailable for this security.
About the company
Scancell Holdings plc is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is a developer of immunotherapies for the treatment of cancer and infectious diseases. The Company is building a pipeline of products by utilizing its four technology platforms: Moditope and ImmunoBody for vaccines and GlyMab and AvidiMab for antibodies. Its products pipeline includes Modi-1, Modi-2, SCIB1 & iSCIB1+, SCIB2 & iSCIB2, SCOV1 and SCOV2 (COVIDITY), as well as Anti-glycan antibodies. Modi-1, which targets citrullinated cancer antigens, is the first therapeutic vaccine candidate to emerge from Scancell's Moditope platform. Modi-2, which targets homocitrullinated cancer antigens, is the second therapeutic vaccine candidate from the Company's Moditope platform. SCIB1 is the lead product from its ImmunoBody immunotherapy platform, which identifies, attacks and destroys tumors. The COVIDITY program, focuses on the Company's COVID-19 vaccine candidates, SCOV1 and SCOV2.
- Revenue in GBP (TTM)0.00
- Net income in GBP-11.32m
- Incorporated2008
- Employees51.00
- LocationScancell Holdings PLCUnit 202 Bellhouse BuildingSanders Road, Oxford Science ParkOXFORD OX4 4GDUnited KingdomGBR
- Phone+44 186 558 2066
- Fax+44 115 823 1863
- Websitehttps://www.scancell.co.uk/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Venture Life Group PLC | 51.41m | 921.00k | 53.13m | 165.00 | 78.80 | 0.6967 | 6.57 | 1.03 | 0.0053 | 0.0053 | 0.3847 | 0.6028 | 0.42 | 2.80 | 3.15 | 311,575.80 | 0.7525 | 1.58 | 0.9274 | 1.83 | 39.19 | 40.14 | 1.79 | 3.99 | 0.7355 | 2.12 | 0.2424 | 0.00 | 16.89 | 22.33 | 77.12 | 31.30 | 18.85 | -- |
| e-Therapeutics plc | 475.00k | -8.27m | 53.61m | 38.00 | -- | 1.62 | -- | 112.87 | -0.0154 | -0.0154 | 0.0009 | 0.0568 | 0.0148 | -- | 1.92 | 12,500.00 | -25.79 | -33.25 | -27.10 | -35.11 | 100.00 | 100.00 | -1,741.90 | -1,490.90 | -- | -- | 0.0089 | -- | -0.4193 | -- | -2.53 | -- | 24.22 | -- |
| Poolbeg Pharma PLC | 0.00 | -4.89m | 57.50m | 12.00 | -- | 3.47 | -- | -- | -0.0098 | -0.0098 | 0.00 | 0.0331 | 0.00 | -- | -- | 0.00 | -25.02 | -- | -25.91 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -100.60 | -- | -- | -- |
| Eco Animal Health Group Plc | 88.46m | -1.62m | 63.68m | 228.00 | -- | 0.7809 | 26.42 | 0.7199 | -0.024 | -0.024 | 1.31 | 1.20 | 0.7664 | 1.92 | 3.41 | 387,986.80 | -0.1949 | 6.03 | -0.2645 | 8.02 | 43.05 | 46.41 | -0.2544 | 7.89 | 2.26 | 1.22 | 0.0437 | 55.72 | 3.79 | 4.89 | 246.94 | -35.90 | -4.43 | -- |
| Celadon Pharmaceuticals PLC | 20.74k | -8.06m | 67.42m | -- | -- | 21.51 | -- | 3,250.69 | -0.1306 | -0.1306 | 0.0003 | 0.0488 | 0.0016 | 267.85 | 0.0248 | -- | -64.68 | -- | -71.16 | -- | -29,080.42 | -- | -40,384.18 | -- | 1.84 | -12.45 | 0.6052 | -- | -- | -- | -- | -- | -- | -- |
| Scancell Holdings Plc | 0.00 | -11.32m | 89.09m | 51.00 | -- | -- | -- | -- | -0.0138 | -0.0138 | 0.00 | -0.0102 | 0.00 | -- | -- | 0.00 | -37.31 | -33.32 | -40.52 | -35.82 | -- | -- | -- | -817.98 | -- | -- | 1.73 | -- | -- | -- | -161.24 | -- | 77.85 | -- |
| Faron Pharmaceuticals Oy | 0.00 | -26.56m | 91.70m | 34.00 | -- | -- | -- | -- | -0.4073 | -0.4073 | 0.00 | -0.1892 | 0.00 | -- | -- | 0.00 | -287.97 | -213.06 | -- | -963.12 | -- | -- | -- | -- | -- | -12.02 | -- | -- | -- | -- | -7.71 | -- | -16.05 | -- |
| Futura Medical PLC | 3.10m | -6.51m | 107.92m | 12.00 | -- | 19.70 | -- | 34.80 | -0.0219 | -0.0219 | 0.0105 | 0.0182 | 0.3391 | -- | 4.73 | -- | -71.22 | -79.25 | -127.75 | -127.22 | 57.22 | -- | -210.03 | -914.37 | 1.47 | -- | -- | -- | -- | -- | -11.40 | -- | 219.68 | -- |
| Creo Medical Group PLC | 29.23m | -25.10m | 126.88m | 279.00 | -- | 1.78 | -- | 4.34 | -0.1139 | -0.1139 | 0.126 | 0.1966 | 0.3318 | 1.87 | 4.14 | 102,926.10 | -28.49 | -- | -34.24 | -- | 48.11 | -- | -85.87 | -- | 3.45 | -- | 0.1177 | -- | 7.98 | -- | -9.52 | -- | -- | -- |
| Animalcare Group Plc | 74.35m | 1.20m | 130.43m | 220.00 | 109.76 | 1.67 | 14.80 | 1.75 | 0.0198 | 0.0198 | 1.22 | 1.30 | 0.6608 | 2.63 | 5.54 | -- | 1.07 | 0.3272 | 1.30 | 0.3866 | 58.30 | 53.62 | 1.61 | 0.5484 | 1.05 | 5.44 | 0.0701 | 599.95 | 3.82 | 0.5138 | -38.98 | -- | -11.79 | 2.59 |
| Holder | Shares | % Held |
|---|---|---|
| Redmile Group LLCas of 20 Dec 2023 | 268.62m | 28.95% |
| Vulpes Investment Management Pte Ltd.as of 28 Dec 2023 | 119.91m | 12.92% |
